- Home
- FGB vs LSB Comparison
FGB vs LSB Comparison
Compare FGB & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGB
- LSB
- Stock Information
- Founded
- FGB 2007
- LSB 2002
- Country
- FGB United States
- LSB China
- Employees
- FGB N/A
- LSB N/A
- Industry
- FGB Finance/Investors Services
- LSB
- Sector
- FGB Finance
- LSB
- Exchange
- FGB Nasdaq
- LSB NYSE
- Market Cap
- FGB 61.9M
- LSB 71.2M
- IPO Year
- FGB N/A
- LSB N/A
- Fundamental
- Price
- FGB $4.36
- LSB $3.70
- Analyst Decision
- FGB
- LSB
- Analyst Count
- FGB 0
- LSB 0
- Target Price
- FGB N/A
- LSB N/A
- AVG Volume (30 Days)
- FGB 53.0K
- LSB 26.3K
- Earning Date
- FGB 01-01-0001
- LSB 01-21-2025
- Dividend Yield
- FGB 8.92%
- LSB N/A
- EPS Growth
- FGB N/A
- LSB N/A
- EPS
- FGB N/A
- LSB N/A
- Revenue
- FGB N/A
- LSB $79,415,311.00
- Revenue This Year
- FGB N/A
- LSB $39.33
- Revenue Next Year
- FGB N/A
- LSB $75.61
- P/E Ratio
- FGB N/A
- LSB N/A
- Revenue Growth
- FGB N/A
- LSB N/A
- 52 Week Low
- FGB $2.85
- LSB $1.88
- 52 Week High
- FGB $3.74
- LSB $11.20
- Technical
- Relative Strength Index (RSI)
- FGB 60.21
- LSB 65.29
- Support Level
- FGB $4.21
- LSB $3.16
- Resistance Level
- FGB $4.48
- LSB $3.83
- Average True Range (ATR)
- FGB 0.10
- LSB 0.44
- MACD
- FGB 0.01
- LSB 0.11
- Stochastic Oscillator
- FGB 67.57
- LSB 92.55
About FGB First Trust Specialty Finance and Financial Opportunities Fund
First Trust Specialty Fnc & Fncl Oppor is a United States-based closed-end management investment company. The Fund's primary investment objective is to seek a high level of current income. It seeks a positive total return as a secondary objective. The Fund seeks to achieve its investment objectives by investing at least 80% of its Managed Assets in a portfolio of securities of specialty finance and other financial companies.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.